Literature DB >> 21377593

Assessment of pulmonary hypertension what CT and MRI can provide.

Yuka Okajima1, Yoshiharu Ohno, George R Washko, Hiroto Hatabu.   

Abstract

RATIONALES AND
OBJECTIVES: Pulmonary hypertension (PH) is a life-threatening condition, characterized by elevated pulmonary arterial pressure, which is confirmed based on invasive right heart catheterization (RHC). Noninvasive examinations may support diagnosis of PH before proceeding to RHC and play an important role in management and treatment of the disease. Although echocardiography is considered a standard tool in diagnosis, recent advances have made computed tomography (CT) and magnetic resonance (MR) imaging promising tools, which may provide morphologic and functional information. In this article, we review image-based assessment of PH with a focus on CT and MR imaging.
CONCLUSIONS: CT may provide useful morphologic information for depicting PH and seeking for underlying diseases. With the accumulated technological advancement, CT and MRI may provide practical tools for not only morphologic but also functional assessment of patients with PH.
Copyright © 2011 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21377593     DOI: 10.1016/j.acra.2011.01.003

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  10 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

2.  Non-invasive determination of pulmonary hypertension with dynamic contrast-enhanced computed tomography: a pilot study.

Authors:  Michael Pienn; Gabor Kovacs; Maria Tscherner; Alexander Avian; Thorsten R Johnson; Peter Kullnig; Rudolf Stollberger; Andrea Olschewski; Horst Olschewski; Zoltán Bálint
Journal:  Eur Radiol       Date:  2013-12-06       Impact factor: 5.315

Review 3.  State-of-the-Art Imaging of the Lung for Connective Tissue Disease (CTD).

Authors:  Yoshiharu Ohno; Hisanobu Koyama; Takeshi Yoshikawa; Shinichiro Seki
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

Review 4.  Pulmonary hypertension: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Eric D Austin; Steven M Kawut; Mark T Gladwin; Steven H Abman
Journal:  Ann Am Thorac Soc       Date:  2014-04

Review 5.  Pulmonary Hypertension and Vascular Abnormalities in Bronchopulmonary Dysplasia.

Authors:  Peter M Mourani; Steven H Abman
Journal:  Clin Perinatol       Date:  2015-09-26       Impact factor: 3.430

6.  Pulmonary arterial hypertension: an update.

Authors:  E S Hoendermis
Journal:  Neth Heart J       Date:  2011-12       Impact factor: 2.380

7.  Use of computed tomography and automated software for quantitative analysis of the vasculature of patients with pulmonary hypertension.

Authors:  Danilo Tadao Wada; Adriana Ignácio de Pádua; Moyses Oliveira Lima Filho; José Antonio Marin Neto; Jorge Elias Júnior; José Baddini-Martinez; Marcel Koenigkam Santos
Journal:  Radiol Bras       Date:  2017 Nov-Dec

Review 8.  Addressing the challenges of phenotyping pediatric pulmonary vascular disease.

Authors:  Kara N Goss; Allen D Everett; Peter M Mourani; Christopher D Baker; Steven H Abman
Journal:  Pulm Circ       Date:  2017-01-01       Impact factor: 3.017

9.  Evaluation of the CT imaging findings in patients newly diagnosed with chronic thromboembolic pulmonary hypertension.

Authors:  Alexandra Grosse; Claudia Grosse; Irene Lang
Journal:  PLoS One       Date:  2018-07-30       Impact factor: 3.240

10.  Quantification of tortuosity and fractal dimension of the lung vessels in pulmonary hypertension patients.

Authors:  Michael Helmberger; Michael Pienn; Martin Urschler; Peter Kullnig; Rudolf Stollberger; Gabor Kovacs; Andrea Olschewski; Horst Olschewski; Zoltán Bálint
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.